biosimilars
A wake-up call
A recent survey found that pharmacist comfort with supplying biosimilars is going backward, so what can be done to turn this around? In 2018, 361 community pharmacists were surveyed across …
Biologics switching is in pharmacists’ scope
Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …
New biosimilars course
Guild Learning and Development is partnering with MSD Australia in an online course titled Biosimilars in focus This is the first of two courses to be launched on this topic …
Innovative medicines prices to drop
Medicines Australia and the Government have signed a five-year agreement which will see innovative medicines reduced in price over 15 years The organisation says the Strategic Agreement will support ongoing …
Caution required for biosimilars
While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug …
Biosimilars: what’s in a name?
The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found. The study, published in …
GBMA welcomes PBS listing of infliximab
The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …
Inflectra to be PBS listed from December
Pfizer today confirmed that the first mAb biosimilar, Inflectra (infliximab), will be added to the PBS on 1 December 2015 for the treatment of eight inflammatory conditions.
Generic Medicines Working Group identifies priorities
Four policy priorities that will safeguard affordable access to medicines in Australia while ensuring the generic and biosimilar medicines industry remains viable have been agreed to by the Federal Government. …
Call for feedback on biosimilars awareness project
The Department of Health is seeking feedback on the Implementation Framework for the Biosimilars Awareness project. The Department of Health says the aim of the project is improve awareness and …
PSA seeks consensus document on biological medicines
The PSA has released its position statement on biologics, stating that it believes a consensus Australian document on terminology and definitions relating to biological medicines, including biosimilar medicines, should be …
GBMA welcomes the ‘a’ flagging of biosimilar infliximab
The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known …